$PLSE
Pulse Biosciences Inc

2021 Q4 Form 10-Q Financial Statement

#000162510121000054 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $844.0K $574.0K $0.00
YoY Change
Cost Of Revenue $1.241M $727.0K
YoY Change
Gross Profit -$397.0K -$153.0K
YoY Change
Gross Profit Margin -47.04% -26.66%
Selling, General & Admin $9.355M $7.660M $5.770M
YoY Change 51.62% 32.76% 2.85%
% of Gross Profit
Research & Development $5.658M $6.460M $6.968M
YoY Change -23.85% -7.29% 12.53%
% of Gross Profit
Depreciation & Amortization $297.0K $100.0K $100.0K
YoY Change 2.41% 0.0% 0.0%
% of Gross Profit
Operating Expenses $15.01M $6.460M $12.91M
YoY Change 9.11% -49.94% 7.87%
Operating Profit -$15.41M -$14.27M -$12.91M
YoY Change 10.6% 9.87%
Interest Expense -$6.000K -$9.000K $9.000K
YoY Change -160.0% -200.0% -95.91%
% of Operating Profit
Other Income/Expense, Net -$9.000K $9.000K
YoY Change -200.0%
Pretax Income -$15.42M -$14.28M -$12.90M
YoY Change 12.12% 10.71% 9.79%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.42M -$14.30M -$12.90M
YoY Change 12.12% 10.89% 9.79%
Net Earnings / Revenue -1826.54% -2491.29%
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$519.8K -$482.3K -$511.5K
COMMON SHARES
Basic Shares Outstanding 29.63M 29.61M 25.21M
Diluted Shares Outstanding 29.61M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.61M $41.99M $29.59M
YoY Change 39.75% 41.91% -14.23%
Cash & Equivalents $28.61M $41.99M $7.070M
Short-Term Investments $0.00 $22.52M
Other Short-Term Assets $2.131M $2.866M $750.0K
YoY Change 14.57% 282.13% -47.92%
Inventory $5.824M $4.281M
Prepaid Expenses
Receivables $61.00K $72.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $36.63M $49.21M $30.33M
YoY Change 63.97% 62.23% -15.59%
LONG-TERM ASSETS
Property, Plant & Equipment $2.462M $2.446M $2.562M
YoY Change -0.65% -4.53% 5.52%
Goodwill $2.791M $2.791M $2.791M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $365.0K $365.0K $365.0K
YoY Change 0.0% 0.0% -77.81%
Total Long-Term Assets $17.62M $17.94M $19.36M
YoY Change -7.04% -7.35% 51.65%
TOTAL ASSETS
Total Short-Term Assets $36.63M $49.21M $30.33M
Total Long-Term Assets $17.62M $17.94M $19.36M
Total Assets $54.25M $67.15M $49.70M
YoY Change 31.38% 35.12% 2.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.904M $2.706M $1.432M
YoY Change 69.13% 88.97% -21.15%
Accrued Expenses $4.389M $4.971M $4.111M
YoY Change -17.59% 20.92% 100.15%
Deferred Revenue $16.00K $7.000K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $436.0K $1.086M
YoY Change
Total Short-Term Liabilities $8.519M $9.519M $6.000M
YoY Change 12.31% 58.65% 48.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.04M $10.24M $10.99M
YoY Change -7.12% -6.81% 199.46%
Total Long-Term Liabilities $10.04M $10.24M $10.99M
YoY Change -7.12% -6.81% 199.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.519M $9.519M $6.000M
Total Long-Term Liabilities $10.04M $10.24M $10.99M
Total Liabilities $18.56M $19.76M $16.99M
YoY Change 0.87% 16.3% 120.06%
SHAREHOLDERS EQUITY
Retained Earnings -$236.2M -$220.8M -$158.8M
YoY Change 36.9% 39.04% 45.82%
Common Stock $271.9M $268.2M $191.5M
YoY Change 39.12% 40.04% 27.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.69M $47.39M $32.70M
YoY Change
Total Liabilities & Shareholders Equity $54.25M $67.15M $49.70M
YoY Change 31.38% 35.12% 2.04%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$15.42M -$14.30M -$12.90M
YoY Change 12.12% 10.89% 9.79%
Depreciation, Depletion And Amortization $297.0K $100.0K $100.0K
YoY Change 2.41% 0.0% 0.0%
Cash From Operating Activities -$12.69M -$13.35M -$8.550M
YoY Change 37.08% 56.14% 7.28%
INVESTING ACTIVITIES
Capital Expenditures -$134.0K -$157.0K -$60.00K
YoY Change -52.14% 161.67% -88.89%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$22.51M
YoY Change -100.0% -100.0% -417.49%
Cash From Investing Activities -$134.0K -$157.0K -$22.57M
YoY Change -100.94% -99.3% -444.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -549.0K 8.072M 430.0K
YoY Change -224.77% 1777.21% 115.0%
NET CHANGE
Cash From Operating Activities -12.69M -13.35M -8.550M
Cash From Investing Activities -134.0K -157.0K -22.57M
Cash From Financing Activities -549.0K 8.072M 430.0K
Net Change In Cash -13.38M -5.435M -30.69M
YoY Change -348.18% -82.29% 2415.57%
FREE CASH FLOW
Cash From Operating Activities -$12.69M -$13.35M -$8.550M
Capital Expenditures -$134.0K -$157.0K -$60.00K
Free Cash Flow -$12.56M -$13.19M -$8.490M
YoY Change 39.87% 55.39% 14.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34899
dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001625101
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
plse Directors And Officers Liability Insurance Period
DirectorsAndOfficersLiabilityInsurancePeriod
P1Y
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5696597
dei Entity Address Address Line1
EntityAddressAddressLine1
3957 Point Eden Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
906-4600
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
PLSE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29631283
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41991000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12463000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
8012000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
72000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4281000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2866000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1864000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
49210000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
22339000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2446000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2478000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3382000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2021Q3 us-gaap Goodwill
Goodwill
2791000
CY2020Q4 us-gaap Goodwill
Goodwill
2791000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8954000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9438000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2021Q3 us-gaap Assets
Assets
67148000
CY2020Q4 us-gaap Assets
Assets
41293000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2706000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1717000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4971000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5326000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
542000
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
1086000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9519000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7585000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10242000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10814000
CY2021Q3 us-gaap Liabilities
Liabilities
19761000
CY2020Q4 us-gaap Liabilities
Liabilities
18399000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29631000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29631000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25550000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25550000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
29000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
268142000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
195410000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220784000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172540000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47387000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67148000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41293000
CY2021Q3 us-gaap Revenues
Revenues
574000
us-gaap Revenues
Revenues
574000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
727000
us-gaap Cost Of Revenue
CostOfRevenue
727000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6460000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6968000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22982000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19019000
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3404000
CY2020Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1746000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10697000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
4926000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4256000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4191000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13772000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12264000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
14847000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
12905000
us-gaap Costs And Expenses
CostsAndExpenses
48178000
us-gaap Costs And Expenses
CostsAndExpenses
36209000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14273000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12905000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47604000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36209000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-9000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-640000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
108000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-640000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14282000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-12896000
us-gaap Net Income Loss
NetIncomeLoss
-48244000
us-gaap Net Income Loss
NetIncomeLoss
-36101000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14282000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12895000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48243000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36104000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.60
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29612000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25223000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27400000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22540000
us-gaap Net Income Loss
NetIncomeLoss
-48244000
us-gaap Net Income Loss
NetIncomeLoss
-36101000
us-gaap Depreciation
Depreciation
349000
us-gaap Depreciation
Depreciation
310000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
499000
us-gaap Share Based Compensation
ShareBasedCompensation
10990000
us-gaap Share Based Compensation
ShareBasedCompensation
7686000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-13000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
6000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-119000
plse Gain Loss On Government Securities
GainLossOnGovernmentSecurities
8000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
72000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4281000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2087000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-431000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-32000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-484000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-352000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-129000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
975000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-595000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-355000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1352000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-365000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-104000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
651000
plse Increase Decrease Other Assets
IncreaseDecreaseOtherAssets
174000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41403000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26110000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
303000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
162000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
25516000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4510000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7697000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4168000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
810000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
490000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4217000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
112000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
678000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
349000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56697000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29498000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1939000
us-gaap Repayments Of Debt
RepaymentsOfDebt
875000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
232000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63234000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30449000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
29528000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
171000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12463000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6899000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41991000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7070000
us-gaap Contribution Of Property
ContributionOfProperty
14000
us-gaap Contribution Of Property
ContributionOfProperty
263000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
1000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-3000
us-gaap Stock Issued1
StockIssued1
629000
plse Issuance Costs For Rights Offering In Accounts Payable
IssuanceCostsForRightsOfferingInAccountsPayable
64000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
389000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1577000
CY2021Q3 plse Adjustments To Additional Paid In Capital Debt Extinguishment And Private Investment Additional Issuance Costs
AdjustmentsToAdditionalPaidInCapitalDebtExtinguishmentAndPrivateInvestmentAdditionalIssuanceCosts
47000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14282000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47387000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
plse Issuance Of Common Stock Issuance Costs
IssuanceOfCommonStockIssuanceCosts
100000
plse Issuance Of Common Stock As Part Of Debt Extinguishment And Private Investment Net Of Issuance Cost
IssuanceOfCommonStockAsPartOfDebtExtinguishmentAndPrivateInvestmentNetOfIssuanceCost
49894000
plse Issuance Of Shares Upon Exercise Of Warrants
IssuanceOfSharesUponExerciseOfWarrants
3334000
plse Issuance Of Common Stock In At Market Equity Offering
IssuanceOfCommonStockInAtMarketEquityOffering
7432000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
810000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-232000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10990000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Net Income Loss
NetIncomeLoss
-48244000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47387000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
42328000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
340000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
235000
CY2020Q3 plse Issuance Of Shares Upon Exercise Of Warrants
IssuanceOfSharesUponExerciseOfWarrants
112000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2648000
CY2020Q3 plse Rights Offering Additional Issuance Costs
RightsOfferingAdditionalIssuanceCosts
64000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2021Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
27000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
349000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
plse Issuance Of Common Stock Issuance Costs
IssuanceOfCommonStockIssuanceCosts
565000
plse Stock Issued During Period Value Rights Offering
StockIssuedDuringPeriodValueRightsOffering
29434000
plse Issuance Of Shares Upon Exercise Of Warrants
IssuanceOfSharesUponExerciseOfWarrants
112000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7686000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-12896000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
32704000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
30737000
us-gaap Net Income Loss
NetIncomeLoss
-36101000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
32704000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41400000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
42000000.0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14300000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the condensed consolidated financial statements. Estimates include, but are not limited to, the valuation of cash equivalents and investments, the valuation and recognition of share-based compensation, inventory valuation, warranty obligations, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. </span></p>
CY2021Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2021Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
27000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
27000
CY2021Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
27000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6023512
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6035192
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
38675000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
17192000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2021Q3 plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1362000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1218000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1701000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4281000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4711000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4394000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2265000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1916000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2446000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2478000
CY2020Q3 us-gaap Depreciation
Depreciation
100000
CY2021Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
300000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4603000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4103000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3382000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3882000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
166000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
665000
CY2014 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
3
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
665000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
665000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
556000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3382000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3549000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3324000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1563000
CY2021Q3 plse Controlled Launch
ControlledLaunch
632000
CY2021Q3 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
367000
CY2020Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
188000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
87000
CY2021Q3 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
27000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
164000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4971000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5326000
CY2014Q4 us-gaap Goodwill
Goodwill
2800000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5039194
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1128338
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
44981
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
111279
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
65263
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5946009
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.73
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3150036
CY2021Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
16.00
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1577000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2649000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10990000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7686000
CY2021Q2 plse Director And Officer Insurance Premium Payable
DirectorAndOfficerInsurancePremiumPayable
2600000
CY2021Q2 plse Insurance Down Payment
InsuranceDownPayment
700000
CY2021Q2 plse Financed Insurance Policy Balance
FinancedInsurancePolicyBalance
1900000
CY2021Q2 plse Financed Insurance Policy Interest Rate
FinancedInsurancePolicyInterestRate
0.0369
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1910000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1976000
CY2021Q3 us-gaap Revenues
Revenues
574000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
447000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1806000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1845000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2046000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6191000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16221000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5230000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10991000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10242000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10991000
us-gaap Operating Lease Payments
OperatingLeasePayments
1196000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y29D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
plse Number Of Kols
NumberOfKols
80
plse Number Of Patients Participating In Procedure
NumberOfPatientsParticipatingInProcedure
40 or 50
CY2021Q3 plse Program Expenses
ProgramExpenses
600000
plse Program Expenses
ProgramExpenses
1200000
CY2021Q3 plse Controlled Launch Revenue Recognized
ControlledLaunchRevenueRecognized
500000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Revenues
Revenues
574000
CY2021Q3 us-gaap Revenues
Revenues
574000
us-gaap Revenues
Revenues
574000

Files In Submission

Name View Source Status
0001625101-21-000054-index-headers.html Edgar Link pending
0001625101-21-000054-index.html Edgar Link pending
0001625101-21-000054.txt Edgar Link pending
0001625101-21-000054-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plse-20210930.xsd Edgar Link pending
plse-20210930x10q.htm Edgar Link pending
plse-20210930x10q_htm.xml Edgar Link completed
plse-20210930xex31_1.htm Edgar Link pending
plse-20210930xex31_2.htm Edgar Link pending
plse-20210930xex32_1.htm Edgar Link pending
plse-20210930_cal.xml Edgar Link unprocessable
plse-20210930_def.xml Edgar Link unprocessable
plse-20210930_lab.xml Edgar Link unprocessable
plse-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending